Company news
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) news
Every Neurocrine Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases — page 6
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2019 Financial Results
February 4, 2020
Neurocrine Biosciences Announces Appointment of Shalini Sharp to Board of Directors
February 3, 2020
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2019 Financial Results
January 20, 2020
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2019 Net Product Sales Results and 2020 Program Milestones
January 12, 2020
Neurocrine Biosciences and Idorsia Amend Option Agreement to License Novel Treatment for Rare Pediatric Epilepsy
January 10, 2020
Neurocrine Biosciences and Xenon Pharmaceuticals Announce Agreement to Develop First-in-Class Treatments for Epilepsy
December 2, 2019
Neurocrine Biosciences Reports Third Quarter 2019 Financial Results
November 4, 2019
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results
October 14, 2019
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
October 4, 2019
Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer
September 30, 2019
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
September 17, 2019
Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors
September 11, 2019
Neurocrine Biosciences Reports Second Quarter 2019 Financial Results
July 29, 2019
Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
July 10, 2019
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results
July 8, 2019
Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference
May 30, 2019
Neurocrine Biosciences and Voyager Therapeutics Announce Phase I Results for VY-AADC in Patients with Parkinson's Disease at the American Academy of Neurology Annual Meeting
May 5, 2019
Neurocrine Biosciences Reports First Quarter 2019 Financial Results
April 29, 2019
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2019 Financial Results
April 8, 2019